Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Blinklab Limited ( (AU:BB1) ).
Blinklab Limited has announced a collaboration with the Netherlands Autism Register and Vrije Universiteit Amsterdam to expand its autism diagnostic capabilities to adults, particularly focusing on late-diagnosed autism and gender disparities. This partnership aims to enhance the company’s market reach and address the underdiagnosis of autism in adults, especially women, by leveraging Blinklab’s neurobehavioral evaluation tools in a study set to begin in April 2025.
More about Blinklab Limited
Blinklab Limited operates within the healthcare industry, focusing on developing diagnostic tools for autism detection. Their primary product, BlinkLab Dx 1, targets autism diagnosis across various age groups, with ongoing trials for children and new studies for adults.
YTD Price Performance: 42.86%
Average Trading Volume: 370,059
Technical Sentiment Consensus Rating: Strong Sell
Learn more about BB1 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue